Sigurdardottir V - Search Results

1

CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.

Lesche D, Sigurdardottir V, Setoud R, Oberhänsli M, Carrel T, Fiedler GM, Largiadèr CR, Mohacsi P, Sistonen J. Lesche D, et al. Among authors: sigurdardottir v. Ther Drug Monit. 2014 Dec;36(6):710-5. doi: 10.1097/FTD.0000000000000080. Ther Drug Monit. 2014. PMID: 24739669 Free article.

2

Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement.

Lesche D, Sigurdardottir V, Leichtle AB, Nakas CT, Christians U, Englberger L, Fiedler M, Largiadèr CR, Mohacsi P, Sistonen J. Lesche D, et al. Among authors: sigurdardottir v. Metabolomics. 2017 Nov 25;14(1):3. doi: 10.1007/s11306-017-1294-8. Metabolomics. 2017. PMID: 30830337 Free article.

3

Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation.

Lesche D, Sigurdardottir V, Setoud R, Englberger L, Fiedler GM, Largiadèr CR, Mohacsi P, Sistonen J. Lesche D, et al. Among authors: sigurdardottir v. Clin Transplant. 2015 Dec;29(12):1213-20. doi: 10.1111/ctr.12653. Epub 2015 Nov 23. Clin Transplant. 2015. PMID: 26458301

4

Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography.

Zanchin C, Yamaji K, Rogge C, Lesche D, Zanchin T, Ueki Y, Windecker S, Mohacsi P, Räber L, Sigurdardottir V. Zanchin C, et al. Among authors: sigurdardottir v. PLoS One. 2018 Aug 27;13(8):e0202950. doi: 10.1371/journal.pone.0202950. eCollection 2018. PLoS One. 2018. PMID: 30148864 Free PMC article.

5

Heart rate kinetics during standard cardiopulmonary exercise testing in heart transplant recipients: a longitudinal study.

Schumacher O, Trachsel LD, Herzig D, Mohacsi P, Sigurdardottir V, Wilhelm M, Eser P. Schumacher O, et al. Among authors: sigurdardottir v. ESC Heart Fail. 2021 Apr;8(2):1096-1105. doi: 10.1002/ehf2.13102. Epub 2021 Jan 8. ESC Heart Fail. 2021. PMID: 33417294 Free PMC article.

6

Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients.

Johansson I, Andersson R, Friman V, Selimovic N, Hanzen L, Nasic S, Nyström U, Sigurdardottir V. Johansson I, et al. Among authors: sigurdardottir v. BMC Infect Dis. 2015 Dec 24;15:582. doi: 10.1186/s12879-015-1321-1. BMC Infect Dis. 2015. PMID: 26703239 Free PMC article.

7

The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.

Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Sigurdardottir V, Dellgren G, Erikstad I, Solberg OG, Ueland T, Aukrust P, Gullestad L; SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators. Arora S, et al. Among authors: sigurdardottir v. Am J Transplant. 2015 Jul;15(7):1967-75. doi: 10.1111/ajt.13214. Epub 2015 Mar 17. Am J Transplant. 2015. PMID: 25783974 Free article. Clinical Trial.

8

Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?

Zuckermann A, Wang SS, Epailly E, Barten MJ, Sigurdardottir V, Segovia J, Varnous S, Turazza FM, Potena L, Lehmkuhl HB. Zuckermann A, et al. Among authors: sigurdardottir v. Transplant Rev (Orlando). 2013 Jul;27(3):76-84. doi: 10.1016/j.trre.2013.03.002. Epub 2013 May 3. Transplant Rev (Orlando). 2013. PMID: 23643624 Review.

9

Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels.

Gustafsson F, Gude E, Sigurdardottir V, Aukrust P, Solbu D, Goetze JP, Gullestad L. Gustafsson F, et al. Among authors: sigurdardottir v. Biomark Med. 2014;8(2):239-45. doi: 10.2217/bmm.13.95. Biomark Med. 2014. PMID: 24521021

10

Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies.

Sigurdardottir V, Bjortuft O, Eiskjær H, Ekmehag B, Gude E, Gustafsson F, Hagerman I, Halme M, Lommi J, Mared L, Riise GC, Simonsen S. Sigurdardottir V, et al. J Heart Lung Transplant. 2012 Dec;31(12):1276-80. doi: 10.1016/j.healun.2012.09.007. Epub 2012 Oct 22. J Heart Lung Transplant. 2012. PMID: 23089300

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters